Quick Answer
Ultragenyx Pharmaceutical Inc. reported Earnings Per Share Diluted of $5.83 (loss) per share for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +7.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $1.63 (loss) per share | Q1 2018: $0.62 per share | Q1 2019: $1.82 (loss) per share | Q2 2019: $1.72 (loss) per share | Q2 2020: $0.41 per share | Q2 2021: $1.81 (loss) per share | Q3 2021: $1.08 (loss) per share | Q1 2022: $2.19 (loss) per share | Q2 2022: $2.26 (loss) per share | Q3 2022: $3.50 (loss) per share | Q1 2023: $2.33 (loss) per share | Q2 2023: $2.25 (loss) per share | Q3 2023: $2.23 (loss) per share | Q1 2024: $2.03 (loss) per share | Q2 2024: $1.52 (loss) per share | Q3 2024: $1.40 (loss) per share | Q1 2025: $1.57 (loss) per share | Q2 2025: $1.17 (loss) per share | Q3 2025: $1.81 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Ultragenyx Pharmaceutical Inc.'s Earnings Per Share Diluted has declined by 89.9%.
- Historical annual values: Fiscal year 2025: $5.83 (loss) per share | Fiscal year 2024: $6.29 (loss) per share | Fiscal year 2023: $8.25 (loss) per share | Fiscal year 2022: $10.12 (loss) per share | Fiscal year 2021: $6.70 (loss) per share | Fiscal year 2020: $3.07 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: